$RGEN
REPLIGEN CORP

2017 Q3 Form 10-Q Financial Statement

#000119312517338561 Filed on November 09, 2017

View on sec.gov

Income Statement

Concept 2017 Q3 2016 Q3
Revenue $36.58M $24.68M
YoY Change 48.24% 24.54%
Cost Of Revenue $19.99M $11.24M
YoY Change 77.79% 33.14%
Gross Profit $16.59M $13.44M
YoY Change 23.51% 18.16%
Gross Profit Margin 45.36% 54.44%
Selling, General & Admin $15.00M $7.127M
YoY Change 110.44% 19.6%
% of Gross Profit 90.39% 53.05%
Research & Development $2.001M $1.886M
YoY Change 6.1% 26.58%
% of Gross Profit 12.06% 14.04%
Depreciation & Amortization $3.090M $1.370M
YoY Change 125.55% 19.13%
% of Gross Profit 18.62% 10.2%
Operating Expenses $36.99M $9.013M
YoY Change 310.36% 21.0%
Operating Profit -$406.0K $3.747M
YoY Change -110.84% 1.6%
Interest Expense $1.618M $1.555M
YoY Change 4.05% 19337.5%
% of Operating Profit 41.5%
Other Income/Expense, Net -$1.616M -$75.00K
YoY Change 2054.67% 97.37%
Pretax Income -$2.022M $2.214M
YoY Change -191.33% -39.82%
Income Tax -$6.691M $1.059M
% Of Pretax Income 47.83%
Net Earnings $4.669M $1.155M
YoY Change 304.24% -54.49%
Net Earnings / Revenue 12.76% 4.68%
Basic Earnings Per Share $0.11 $0.03
Diluted Earnings Per Share $0.11 $0.03
COMMON SHARES
Basic Shares Outstanding 41.24M shares 33.78M shares
Diluted Shares Outstanding 42.56M shares 34.31M shares

Balance Sheet

Concept 2017 Q3 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $159.7M $178.7M
YoY Change -10.63% 159.36%
Cash & Equivalents $159.7M $157.7M
Short-Term Investments $0.00 $21.10M
Other Short-Term Assets $2.800M $1.300M
YoY Change 115.38% 18.18%
Inventory $38.66M $24.46M
Prepaid Expenses
Receivables $29.48M $15.15M
Other Receivables $600.0K $200.0K
Total Short-Term Assets $231.2M $219.8M
YoY Change 5.17% 128.33%
LONG-TERM ASSETS
Property, Plant & Equipment $22.06M $14.94M
YoY Change 47.68% 6.88%
Goodwill $326.7M $31.16M
YoY Change 948.27% 117.21%
Intangibles $147.4M $18.67M
YoY Change 689.55% 41.94%
Long-Term Investments $0.00
YoY Change -100.0%
Other Assets $6.467M $500.0K
YoY Change 1193.4% 0.0%
Total Long-Term Assets $503.0M $65.22M
YoY Change 671.33% 49.67%
TOTAL ASSETS
Total Short-Term Assets $231.2M $219.8M
Total Long-Term Assets $503.0M $65.22M
Total Assets $734.2M $285.1M
YoY Change 157.58% 103.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.423M $5.061M
YoY Change 26.91% 71.5%
Accrued Expenses $13.79M $15.13M
YoY Change -8.84% 18.6%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $98.20M
YoY Change
Total Short-Term Liabilities $118.4M $20.19M
YoY Change 486.6% 28.54%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $94.30M
YoY Change -100.0%
Other Long-Term Liabilities $1.573M $1.894M
YoY Change -16.95% -29.67%
Total Long-Term Liabilities $1.573M $1.894M
YoY Change -16.95% -29.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $118.4M $20.19M
Total Long-Term Liabilities $1.573M $1.894M
Total Liabilities $120.0M $22.09M
YoY Change 443.42% 20.02%
SHAREHOLDERS EQUITY
Retained Earnings -$43.69M -$64.89M
YoY Change -32.68% -9.63%
Common Stock $627.2M $240.9M
YoY Change 160.35% 19.27%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $576.9M $166.5M
YoY Change
Total Liabilities & Shareholders Equity $734.2M $285.1M
YoY Change 157.58% 103.82%

Cashflow Statement

Concept 2017 Q3 2016 Q3
OPERATING ACTIVITIES
Net Income $4.669M $1.155M
YoY Change 304.24% -54.49%
Depreciation, Depletion And Amortization $3.090M $1.370M
YoY Change 125.55% 19.13%
Cash From Operating Activities -$1.730M -$1.180M
YoY Change 46.61% -117.91%
INVESTING ACTIVITIES
Capital Expenditures -$1.010M -$2.050M
YoY Change -50.73% 540.62%
Acquisitions
YoY Change
Other Investing Activities -$110.2M -$11.85M
YoY Change 829.96% -713.99%
Cash From Investing Activities -$111.2M -$13.90M
YoY Change 700.07% -958.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $129.3M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 129.8M 420.0K
YoY Change 30807.14% 75.0%
NET CHANGE
Cash From Operating Activities -1.730M -1.180M
Cash From Investing Activities -111.2M -13.90M
Cash From Financing Activities 129.8M 420.0K
Net Change In Cash 16.87M -14.66M
YoY Change -215.08% -273.49%
FREE CASH FLOW
Cash From Operating Activities -$1.730M -$1.180M
Capital Expenditures -$1.010M -$2.050M
Free Cash Flow -$720.0K $870.0K
YoY Change -182.76% -87.41%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43565306 shares
CY2017Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2807017 shares
CY2017Q3 rgen Common Stock Issue Price Per Share
CommonStockIssuePricePerShare
42.75
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
157651000
CY2017Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
20.74
CY2017Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2017Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43559081 shares
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
739381 shares
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1228987 shares
CY2017Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43559081 shares
CY2017Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
423217 shares
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
15.86
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
749669 shares
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
20.84
CY2017Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q3 us-gaap Share Price
SharePrice
38.32
CY2017Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-43686000
CY2017Q3 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
528000
CY2017Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1573000
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
3367000
CY2017Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
734236000
CY2017Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
406000
CY2017Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6497000
CY2017Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1299000
CY2017Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6647000
CY2017Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
6423000
CY2017Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
448000
CY2017Q3 us-gaap Stockholders Equity
StockholdersEquity
576869000
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
939000
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
2751000
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
3644000
CY2017Q3 us-gaap Interest Payable Current
InterestPayableCurrent
806000
CY2017Q3 us-gaap Common Stock Value
CommonStockValue
436000
CY2017Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
626766000
CY2017Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
22416000
CY2017Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
734000
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
3060000
CY2017Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
10611000
CY2017Q3 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
37347000
CY2017Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
32000
CY2017Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
591000
CY2017Q3 us-gaap Other Liabilities Fair Value Disclosure
OtherLiabilitiesFairValueDisclosure
0
CY2017Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1826000
CY2017Q3 us-gaap Liabilities Current
LiabilitiesCurrent
118447000
CY2017Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
98231000
CY2017Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
1064000
CY2017Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13793000
CY2017Q3 us-gaap Assets Current
AssetsCurrent
231195000
CY2017Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
3633000
CY2017Q3 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
19543000
CY2017Q3 us-gaap Other Receivables Gross Current
OtherReceivablesGrossCurrent
598000
CY2017Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
44472000
CY2017Q3 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
4111000
CY2017Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22056000
CY2017Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
450000
CY2017Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
9602000
CY2017Q3 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
0
CY2017Q3 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
768000
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
159666000
CY2017Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
18114000
CY2017Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
9619000
CY2017Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
147416000
CY2017Q3 us-gaap Inventory Net
InventoryNet
38663000
CY2017Q3 us-gaap Land
Land
1021000
CY2017Q3 us-gaap Other Assets Fair Value Disclosure
OtherAssetsFairValueDisclosure
0
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
13065000
CY2017Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
29479000
CY2017Q3 us-gaap Construction In Progress Gross
ConstructionInProgressGross
3286000
CY2017Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
2625000
CY2017Q3 us-gaap Assets
Assets
734236000
CY2017Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
9046000
CY2017Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
10214000
CY2017Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
10308000
CY2017Q3 us-gaap Goodwill
Goodwill
326652000
CY2017Q3 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
158027000
CY2017Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
12795000
CY2017Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
22235000
CY2017Q3 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
15743000
CY2017Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6467000
CY2017Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2789000
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
13205000
CY2017Q3 rgen Operating Lease Future Minimum Payments Due In Four Years And Thereafter
OperatingLeaseFutureMinimumPaymentsDueInFourYearsAndThereafter
2319000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54092000
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33844074 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33844074 shares
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
882748 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.88
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
786000
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-59861000
CY2016Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
178000
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1699000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
288913000
CY2016Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
435000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5586000
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
408000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-13749000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5061000
CY2016Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
382000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
168764000
CY2016Q4 us-gaap Interest Payable Current
InterestPayableCurrent
204000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
338000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
242036000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
19332000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
411000
CY2016Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
6695000
CY2016Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
2103000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
23000
CY2016Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1692000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21075000
CY2016Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
6119000
CY2016Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
95272000
CY2016Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
6119000
CY2016Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
248000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16014000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
184153000
CY2016Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2789000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14956000
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
450000
CY2016Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
19547000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
122233000
CY2016Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
29806000
CY2016Q4 us-gaap Inventory Net
InventoryNet
24696000
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15194000
CY2016Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
1264000
CY2016Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
3218000
CY2016Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
15214000
CY2016Q4 us-gaap Other Receivables Gross Current
OtherReceivablesGrossCurrent
839000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
34288000
CY2016Q4 us-gaap Assets
Assets
288913000
CY2016Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
0
CY2016Q4 us-gaap Goodwill
Goodwill
59548000
CY2016Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
36501000
CY2016Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
6953000
CY2016Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
14954000
CY2016Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
14592000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1644000
CY2017Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
129300000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
326572 shares
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
dei Document Type
DocumentType
10-Q
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.43
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34 pure
dei Entity Central Index Key
EntityCentralIndexKey
0000730272
us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P16Y
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
2233000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
32957 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M19D
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
10.08
dei Trading Symbol
TradingSymbol
RGEN
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37386333 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36435591 shares
dei Amendment Flag
AmendmentFlag
false
us-gaap Incremental Common Shares Attributable To Participating Nonvested Shares With Non Forfeitable Dividend Rights
IncrementalCommonSharesAttributableToParticipatingNonvestedSharesWithNonForfeitableDividendRights
0 shares
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
33.38
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y6M10D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
16.94
us-gaap Basis Of Accounting
BasisOfAccounting
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> <b>1. Basis of Presentation</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The condensed consolidated financial statements included herein have been prepared by Repligen Corporation (the &#x201C;Company,&#x201D; &#x201C;Repligen&#x201D; or &#x201C;we&#x201D;) in accordance with generally accepted accounting principles in the United States (&#x201C;U.S. GAAP&#x201D;) and pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201C;SEC&#x201D;), for Quarterly Reports on Form <font style="WHITE-SPACE: nowrap">10-Q</font> and Article 10 of Regulation <font style="WHITE-SPACE: nowrap">S-X</font> and do not include all of the information and footnote disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes thereto included in the Company&#x2019;s Annual Report on Form <font style="WHITE-SPACE: nowrap">10-K</font> for the fiscal year ended December&#xA0;31, 2016.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Repligen Sweden AB (&#x201C;Repligen Sweden&#x201D;), Repligen GmbH (acquired as Atoll GmbH on April&#xA0;1, 2016 and renamed on September&#xA0;20, 2016), Repligen Singapore Pte. Ltd., our former subsidiary, TangenX Technology Corporation (&#x201C;TangenX,&#x201D; acquired on December&#xA0;14, 2016 and merged into the Company as of June&#xA0;30, 2017) and Spectrum LifeSciences, LLC (&#x201C;Spectrum,&#x201D; acquired on August&#xA0;1, 2017). All significant intercompany accounts and transactions have been eliminated in consolidation.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of only normal, recurring adjustments necessary for a fair presentation of the financial position, results of operations and cash flows. The results of operations for the interim periods presented are not necessarily indicative of results to be expected for the entire year.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Recently Issued Accounting Pronouncements</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> In May 2014, the FASB issued ASU <font style="WHITE-SPACE: nowrap">No.&#xA0;2014-09,</font> &#x201C;Revenue from Contracts with Customers (Topic 606),&#x201D; which supersedes the revenue recognition requirements in Accounting Standards Codification Topic 605, <i>Revenue Recognition</i>, and creates a new Topic 606, <i>Revenue from Contracts with Customers</i>. Two adoption methods are permitted: retrospectively to all prior reporting periods presented, with certain practical expedients permitted; or retrospectively with the cumulative effect of initially adopting the ASU recognized at the date of initial application. The adoption of this ASU will include updates as provided under ASU <font style="WHITE-SPACE: nowrap">2015-14,</font> &#x201C;Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date&#x201D;;&#xA0;ASU <font style="WHITE-SPACE: nowrap">2016-08,</font> &#x201C;Revenue from Contracts with Customers (Topic&#xA0;606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net)&#x201D;; ASU <font style="WHITE-SPACE: nowrap">2016-10,</font> &#x201C;Revenue from Contracts with Customers (Topic&#xA0;606): Identifying Performance Obligations and Licensing&#x201D;; and ASU <font style="WHITE-SPACE: nowrap">2016-12,</font> &#x201C;Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients.&#x201D; The Company intends to adopt the provisions of Topic 606 using the modified retrospective method effective January&#xA0;1, 2018. The Company has substantially completed its assessment of the impact of the new revenue standard on the current contracts of all principal revenue streams except those related to the recently acquired business of Spectrum. The Company will complete its assessment of the impact of the new revenue standard on Spectrum&#x2019;s revenue arrangements in the fourth quarter of 2017. The Company is currently updating its revenue recognition policies and procedures and developing a framework for the newly required financial statement disclosures. While the Company has not made a final determination on the impact of this new revenue standard to its consolidated financial statements, it does not expect this impact to be material.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> In July 2015, the FASB issued ASU <font style="WHITE-SPACE: nowrap">No.&#xA0;2015-11,</font> &#x201C;Inventory (Topic 330): Simplifying the Measurement of Inventory&#x201D; (&#x201C;ASU <font style="WHITE-SPACE: nowrap">2015-11&#x201D;).</font> ASU <font style="WHITE-SPACE: nowrap">2015-11</font> requires inventory be measured at the lower of cost and net realizable value, and options that currently exist for market value be eliminated. ASU <font style="WHITE-SPACE: nowrap">2015-11</font> defines net realizable value as estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The guidance is effective prospectively for reporting periods beginning after December&#xA0;15, 2016 and interim periods within those fiscal years with early adoption permitted. The Company adopted the provisions of ASU <font style="WHITE-SPACE: nowrap">2015-11</font> as of January&#xA0;1, 2017, and this standard did not have a material impact on its consolidated financial statements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> In January 2016, the FASB issued ASU <font style="WHITE-SPACE: nowrap">No.&#xA0;2016-01,</font> &#x201C;Financial Instruments - Overall (Subtopic <font style="WHITE-SPACE: nowrap">825-10):</font> Recognition and Measurement of Financial Assets and Financial Liabilities.&#x201D; (&#x201C;ASU <font style="WHITE-SPACE: nowrap">2016-01&#x201D;)</font> This guidance changes how entities measure equity investments that do not result in consolidation and are not accounted for under the equity method. Entities will be required to measure these investments at fair value at the end of each reporting period and recognize changes in fair value in net income. A practicability exception will be available for equity investments that do not have readily determinable fair values; however, the exception requires the Company to consider relevant transactions that can be&#xA0;reasonably known to identify any observable price changes that would impact the fair value. This guidance also changes certain disclosure requirements and other aspects of current U.S. GAAP. This guidance is effective for annual periods beginning after December&#xA0;15, 2017, and is applicable to the Company in 2018. Upon adoption, the Company will be required to recognize unrealized gains and losses on its equity securities directly through the Company&#x2019;s consolidated statements of operations, whereas these equity securities currently are designated as available for sale, and unrealized gains and losses are recognized within accumulated other comprehensive income.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> In February 2016, the FASB issued ASU No. <font style="WHITE-SPACE: nowrap">2016-02,&#xA0;&#x201C;Leases</font> (Topic 842)&#x201D; (&#x201C;ASU <font style="WHITE-SPACE: nowrap">2016-02&#x201D;).</font> ASU <font style="WHITE-SPACE: nowrap">2016-02</font> requires lessees to recognize a <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">right-of-use</font></font> asset and a lease liability for most leases. Extensive quantitative and qualitative disclosures, including significant judgments made by management, will be required to provide greater insight into the extent of revenue and expense recognized and expected to be recognized from existing contracts. The accounting applied by a lessor is largely unchanged from that applied under the current standard. The standard must be adopted using a modified retrospective transition approach and provides for certain practical expedients. This ASU is effective for public entities for fiscal years beginning after December&#xA0;15, 2018, with early adoption permitted. The Company has not assessed the impact of the new standard on its consolidated financial statements, but does expect this new standard to have a material impact on the Company&#x2019;s consolidated balance sheet.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> In March 2016, the FASB issued ASU No. <font style="WHITE-SPACE: nowrap">2016-09,&#xA0;&#x201C;Compensation&#x2014;Stock</font> Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting&#x201D;, which aims to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, classification of certain items on the statement of cash flows and accounting for forfeitures. This ASU is effective for public entities for fiscal years beginning after December&#xA0;15, 2016, with early adoption permitted. The Company adopted the provisions of this ASU as of January&#xA0;1, 2017. As a result of this standard, the Company increased its U.S. federal and state net operating loss carryovers by approximately $5.3&#xA0;million for previously unrecognized excess tax benefits outstanding as of January&#xA0;1, 2017. Since the Company maintained a full valuation allowance on its net U.S. deferred tax assets as of the adoption date, the Company recorded a corresponding increase to the valuation allowance and the impact of adopting ASU <font style="WHITE-SPACE: nowrap">2016-09</font> on retained earnings is zero.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> In August 2016, the FASB issued ASU <font style="WHITE-SPACE: nowrap">No.&#xA0;2016-15,</font> &#x201C;Statement of Cash Flows (Topic 203): Classification of Certain Cash Receipts and Cash Payments&#x201D;. ASU <font style="WHITE-SPACE: nowrap">No.&#xA0;2016-15</font> addresses eight specific cash flow issues and clarifies their presentation and classification in the Statement of Cash Flows. This ASU is effective for fiscal years beginning after December&#xA0;15, 2017 and is to be applied retrospectively with early adoption permitted. The Company currently classifies payments up to the amount of its contingent consideration liability recognized at the date of its acquisition as financing activities, with additional payments classified as operating activities. As a result, the Company does not expect the adoption of ASU <font style="WHITE-SPACE: nowrap">2016-15</font> to have a material impact on its consolidated financial statements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> In January 2017, the FASB issued ASU&#xA0;No. <font style="WHITE-SPACE: nowrap">2017-01,&#xA0;&#x201C;Business</font> Combinations (Topic 805): Clarifying the Definition of a Business&#x201D;, which clarifies the definition of a business to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. This ASU is effective for public entities for fiscal years beginning after December&#xA0;15, 2017, with early adoption permitted. The Company does not expect the adoption of ASU <font style="WHITE-SPACE: nowrap">2017-01</font> to have a material impact on the Company&#x2019;s consolidated financial statements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> In January 2017, the FASB issued ASU <font style="WHITE-SPACE: nowrap">No.&#xA0;2017-04,</font> &#x201C;Intangibles&#x2013;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment,&#x201D; eliminating the requirement to calculate the implied fair value, essentially eliminating step two from the goodwill impairment test. The new standard requires goodwill impairment to be based upon the results of step one of the impairment test, which is defined as the excess of the carrying value of a reporting unit over its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. The standard is effective for the Company on a prospective basis beginning on January&#xA0;1, 2020, with early adoption permitted. This new guidance is not expected to have a material impact on the Company&#x2019;s consolidated financial statements.</p> </div>
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.44
dei Document Period End Date
DocumentPeriodEndDate
2017-09-30
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
454340 shares
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
201966 shares
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-1.838 pure
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M
dei Entity Registrant Name
EntityRegistrantName
REPLIGEN CORP
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
496402 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
20.31
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
101844 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y8M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2074000
us-gaap Revenues
Revenues
99624000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3686000
us-gaap Investment Income Net
InvestmentIncomeNet
308000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
704000
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
99516000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
48000
us-gaap Payments Of Merger Related Costs Financing Activities
PaymentsOfMergerRelatedCostsFinancingActivities
1702000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
5000
us-gaap Operating Income Loss
OperatingIncomeLoss
10743000
us-gaap Net Income Loss
NetIncomeLoss
16175000
us-gaap Interest Paid
InterestPaid
1222000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-699000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
8472000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
23277000
us-gaap Royalty Revenue
RoyaltyRevenue
108000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
7097000
us-gaap Income Taxes Paid
IncomeTaxesPaid
3555000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-548000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-196000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
739000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
5699000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-64000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-13062000
us-gaap Depreciation
Depreciation
2988000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
2633000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-10476000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
159000
us-gaap Interest Expense
InterestExpense
4804000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-97075000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
129309000
us-gaap Share Based Compensation
ShareBasedCompensation
4845000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2958000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
6374000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
35365000
us-gaap Costs And Expenses
CostsAndExpenses
88881000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-6089000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
129642000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5603000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3476000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
37433000
us-gaap Cost Of Goods Sold
CostOfGoodsSold
47913000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
6119000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
19600000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2035000
rgen Increase Decrease In Noncurrent Liabilities
IncreaseDecreaseInNoncurrentLiabilities
-171000
rgen Payment Of Contingent Consideration In Common Stock
PaymentOfContingentConsiderationInCommonStock
1062000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
348608 shares
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.20
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34 pure
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
5567000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34011534 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33485448 shares
us-gaap Incremental Common Shares Attributable To Participating Nonvested Shares With Non Forfeitable Dividend Rights
IncrementalCommonSharesAttributableToParticipatingNonvestedSharesWithNonForfeitableDividendRights
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
13.55
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.20
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
526086 shares
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.343 pure
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1590000
us-gaap Revenues
Revenues
78942000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3462000
us-gaap Investment Income Net
InvestmentIncomeNet
234000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
15000
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
78942000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
21394000
us-gaap Payments Of Merger Related Costs Financing Activities
PaymentsOfMergerRelatedCostsFinancingActivities
498000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
89000
us-gaap Operating Income Loss
OperatingIncomeLoss
13068000
us-gaap Net Income Loss
NetIncomeLoss
6651000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
6457000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3270000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
5721000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1019000
us-gaap Income Taxes Paid
IncomeTaxesPaid
2888000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-979000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-20000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-820000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
10125000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-25000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
3317000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
326000
us-gaap Depreciation
Depreciation
2360000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-332000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3474000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1918000
us-gaap Interest Expense
InterestExpense
2198000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-13878000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
45000
us-gaap Share Based Compensation
ShareBasedCompensation
3341000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1320000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3844000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
111070000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
22286000
us-gaap Costs And Expenses
CostsAndExpenses
65874000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2389000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
112202000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5316000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1484000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
103559000
us-gaap Cost Of Goods Sold
CostOfGoodsSold
34955000
CY2016Q3 us-gaap Revenues
Revenues
24677000
CY2016Q3 us-gaap Investment Income Net
InvestmentIncomeNet
97000
CY2016Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
24677000
CY2016Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
74000
CY2016Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0 shares
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
19700000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1630000
rgen Increase Decrease In Noncurrent Liabilities
IncreaseDecreaseInNoncurrentLiabilities
-48000
rgen Payment Of Contingent Consideration In Common Stock
PaymentOfContingentConsiderationInCommonStock
875000
CY2016 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P13Y
CY2016 rgen Long Term Marketable Securities Maturities Term Minimum
LongTermMarketableSecuritiesMaturitiesTermMinimum
P1Y
CY2017Q2 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-9200000
CY2016Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
253754 shares
CY2016Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03
CY2016Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34 pure
CY2016Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34312887 shares
CY2016Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33779141 shares
CY2016Q3 us-gaap Incremental Common Shares Attributable To Participating Nonvested Shares With Non Forfeitable Dividend Rights
IncrementalCommonSharesAttributableToParticipatingNonvestedSharesWithNonForfeitableDividendRights
0 shares
CY2016Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2016Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
533746 shares
CY2016Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.478 pure
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
3747000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
1155000
CY2016Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
843000
CY2016Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-386000
CY2016Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-75000
CY2016Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
2214000
CY2016Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
675000
CY2016Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1059000
CY2016Q3 us-gaap Interest Expense
InterestExpense
1555000
CY2016Q3 us-gaap Share Based Compensation
ShareBasedCompensation
1282000
CY2016Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7127000
CY2016Q3 us-gaap Costs And Expenses
CostsAndExpenses
20930000
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1886000
CY2016Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
11242000
CY2017Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
162544 shares
CY2017Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.11
CY2017Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34 pure
CY2017Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42563002 shares
CY2017Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41236554 shares
CY2017Q3 us-gaap Incremental Common Shares Attributable To Participating Nonvested Shares With Non Forfeitable Dividend Rights
IncrementalCommonSharesAttributableToParticipatingNonvestedSharesWithNonForfeitableDividendRights
0 shares
CY2017Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.11
CY2017Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
484242 shares
CY2017Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
3.309 pure
CY2017Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
842206 shares
CY2017Q3 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-6611000
CY2017Q3 us-gaap Revenues
Revenues
36580000
CY2017Q3 us-gaap Investment Income Net
InvestmentIncomeNet
102000
CY2017Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
36514000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-406000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
4669000
CY2017Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
6694000
CY2017Q3 us-gaap Royalty Revenue
RoyaltyRevenue
66000
CY2017Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2025000
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-100000
CY2017Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2022000
CY2017Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-6691000
CY2017Q3 us-gaap Interest Expense
InterestExpense
1618000
CY2017Q3 us-gaap Share Based Compensation
ShareBasedCompensation
1817000
CY2017Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14998000
CY2017Q3 us-gaap Costs And Expenses
CostsAndExpenses
36986000
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2001000
CY2017Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
19987000

Files In Submission

Name View Source Status
0001193125-17-338561-index-headers.html Edgar Link pending
0001193125-17-338561-index.html Edgar Link pending
0001193125-17-338561.txt Edgar Link pending
0001193125-17-338561-xbrl.zip Edgar Link pending
d464245d10q.htm Edgar Link pending
d464245dex311.htm Edgar Link pending
d464245dex312.htm Edgar Link pending
d464245dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rgen-20170930.xml Edgar Link completed
rgen-20170930.xsd Edgar Link pending
rgen-20170930_cal.xml Edgar Link unprocessable
rgen-20170930_def.xml Edgar Link unprocessable
rgen-20170930_lab.xml Edgar Link unprocessable
rgen-20170930_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending